ARWR (Arrowhead Pharmaceuticals) Other Net Income (Loss) : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Other Net Income (Loss)?

Arrowhead Pharmaceuticals's Other Net Income (Loss) for the three months ended in Sep. 2024 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Arrowhead Pharmaceuticals's annual Other Net Income (Loss) stayed the same from Sep. 2022 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then declined from Sep. 2023 ($0.00 Mil) to Sep. 2024 ($-0.00 Mil).

Arrowhead Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Other Net Income (Loss) Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Other Net Income (Loss)

Get a 7-Day Free Trial

Arrowhead Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Arrowhead Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Arrowhead Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

ARWR:Mexico 0HI3:UK HDP1:Germany HDP1:Germany

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Executives

Tracie Oliver	officer: Chief Commercial Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James C Hamilton	other: Senior Vice President	177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Kenneth Allen Myszkowski	officer: CFO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone	director, officer: President and CEO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Mauro Ferrari	director	201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Patrick O'brien	officer: General Counsel	225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San	officer: Chief Medical Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105